Pharmaceutical Technology

JUNE 24, 2025

Can pharma tariffs “Make America Manufacture Again”?

Compounding 52

Compounding Packaging Online Pharmacies Communication 52

pharmaphorum

JULY 24, 2025

R&D Deep Dive: Research and Development 2025 Every breakthrough in medicine, every new treatment that changes lives, starts with research. R&D Life Sciences Industry Report - Biologics and Generics The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.

Diabetes 66

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 66

pharmaphorum

JUNE 30, 2025

Can you give a brief overview of why the historical development of new treatments for neurodevelopmental disorders has faced significant challenges? With the right teams and experience in place, drug developers can unlock their full potential, streamline efforts to advance them quickly, and bring more, new options to patients.

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Drug Development 52

Pharmaceutical Technology

JUNE 17, 2025

TEV-56278 demonstrates the strength of Teva’s innovative drug development capabilities and how strategic partnerships with companies such as Fosun Pharma play a pivotal role in advancing therapies on behalf of patients.” Can pharma tariffs “Make America Manufacture Again”? Sign up for our daily news round-up!

Communication 52

Communication Hospitals Drug Development Packaging 52

Pharmaceutical Technology

JUNE 27, 2025

Trump’s ‘most favoured nation’ model comes at a time when the administration has been vocal on its support for generics and biosimilars – copycat drugs that offer patients a cheaper entry point to treatment. It also goes some way to explaining the sheer volume of patients turning to compounded GLP-1RAs for weight loss.

Drug Pricing 59

Drug Pricing Compounding Packaging Communication 59

pharmaphorum

JULY 2, 2025

The ability to streamline clinical trials, personalise treatments, and accelerate drug development is groundbreaking. A recent report found that 64% of pharmaceutical executives are hesitant to integrate AI into drug development due to concerns over security. The opportunity ahead is enormous.

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Drug Development 52

Pharmaceutical Technology

JUNE 25, 2025

Over the past few decades, Alzheimer’s research and development (R&D) has seen a low success rate due to failure to demonstrate efficacy in clinical trials. Go deeper with GlobalData Reports Biosimilars in Pharmaceuticals: Peptide-based compositions for Alzh. Can pharma tariffs “Make America Manufacture Again”?

Packaging 59

Packaging Biosimilars Communication Hospitals 59

pharmaphorum

JUNE 17, 2025

If completed, it will be Lillys third major acquisition in 2025, coming after it agreed to buy cancer drug developer Scorpion Therapeutics for up to $2.5 R&D Deep Dive: Research and Development 2025 Every breakthrough in medicine, every new treatment that changes lives, starts with research.

Diabetes 59

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 59

pharmaphorum

JUNE 27, 2025

R&D Deep Dive: Research and Development 2025 Every breakthrough in medicine, every new treatment that changes lives, starts with research. R&D Life Sciences Industry Report - Biologics and Generics The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.

Drug Development 52

Drug Development Diabetes Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JULY 17, 2025

The 7th Inflammasome Therapeutics Summit is your go-to forum for drug developers, translational scientists, and immunology innovators striving to push inflammasome-targeted therapies from concept to clinic. If you are serious about leading the charge in inflammasome drug development, this is where the future takes shape.

Immunity 52

Immunity Immunization Diabetes Pharmaceutical Companies 52

pharmaphorum

JUNE 17, 2025

Its precision medicine approach – directed mainly at cancer – is being deployed in the development of tools for detection, diagnosis, monitoring, therapy selection, and drug development, driven by genomic data, clinical data, digitised medical images, and tissue samples.

Diabetes 89

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 89

pharmaphorum

JUNE 27, 2025

The obesity drug market is exploding into a $100 billion opportunity, fuelled by breakthroughs in GLP-1 combinations, novel targets like GIPR modulators, and RNA-based therapies. R&D Deep Dive: Research and Development 2025 Every breakthrough in medicine, every new treatment that changes lives, starts with research.

Drug Development 52

Drug Development Diabetes Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JUNE 24, 2025

All this recent excitement has confirmed that RWE will continue to play a pivotal role in drug development, yet questions still remain for the experts responsible for its application. R&D Deep Dive: Research and Development 2025 Every breakthrough in medicine, every new treatment that changes lives, starts with research.

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Drug Development 52

pharmaphorum

JUNE 10, 2025

Image Phil Taylor 10 June, 2025 customer engagement Bookmark this R&D Transforming drug development with statistical methodologies The product development lifecycle is long and challenging. Sales & Marketing Sponsored Vault CRM Campaign Manager: Supporting high growth by synchr.

Diabetes 95

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 95